| Humira (adalimumab) / AbbVie |
Adherence, NCT01768858: Assessment of Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Plaque Psoriasis, Crohn's Disease and Ulcerative Colitis Patients´ Attitudes to Maintenance Therapy With a Scheduled Adalimumab Treatment in Routine Clinical Practice |
|
|
| Completed | N/A | 96 | NA | Adalimumab, Humira, ABT-D2E7 | AbbVie, Raffeiner GmbH | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Crohn´s Disease, Ulcerative Colitis, Plaque Psoriasis | 08/17 | 08/17 | | |
AGIL, NCT01076205: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis |
|
|
| Completed | N/A | 7229 | NA | | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 09/17 | 09/17 | | |
Re-Bone, NCT02778789: Comparing the Efficacy of Periarticular Bone Structure in Patients Treated With Either Tocilizumab or Tumor Necrosis Factor Blockers |
|
|
| Completed | N/A | 66 | Europe | Tocilizumab, RoActemra, TNF-alpha Inhibitor, Adalimumab, Etanercept, Golimumab, Certolizumab-Pegol, Infliximab | University of Erlangen-Nürnberg Medical School | Rheumatoid Arthritis | 09/17 | 03/18 | | |
NCT02616380: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan |
|
|
| Completed | N/A | 100 | NA | | AbbVie | Rheumatoid Arthritis | 11/17 | 11/17 | | |
VITALITY, NCT02451839: An ObserVatIonal STudy of the Effectiveness of AdaLimumab on Health and Disability Outcomes in New Zealand Patients With Immune-Mediated InflammaTorY Diseases |
|
|
| Completed | N/A | 168 | NA | | AbbVie | Crohn's Disease, Rheumatoid Arthritis, Psoriasis | 12/17 | 12/17 | | |
NCT02539849: Effect of Prebiotic FOS on Intestinal Abundance of Faecalibacterium Prausnitzii in Patients With Crohn´s Disease |
|
|
| Completed | N/A | 38 | Europe | FOS, Adalimumab | Hospital Universitari Vall d'Hebron Research Institute, AbbVie | Crohn Disease | 12/17 | 12/17 | | |
NCT01329380: Special Investigation in Patients With Ankylosing Spondylitis (All Patients Investigation) |
|
|
| Completed | N/A | 403 | Japan | | AbbVie | Ankylosing Spondylitis | 12/17 | 12/17 | | |
| Completed | N/A | 91 | NA | | AbbVie | Rheumatoid Arthritis | 12/17 | 12/17 | | |
NCT03496831: Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs |
|
|
| Completed | N/A | 7500 | NA | Biologic Agents, Abatacept, Adalimumab, Anakinra, Certolizumab, Etanercept, Golimumab, Infliximab, Rituximab, Secukinumab, Tocilizumab, Ustekinumab | Simon Krabbe, University of Aarhus, Zealand University Hospital, University of Southern Denmark | Rheumatoid Arthritis, Spondyloarthritis, Psoriatic Arthritis | 12/17 | 12/17 | | |
NCT03043677: Ex-vivo Modulatory Effect of Biological Drugs for Inflammatory Bowel Disease on the Mucosa and on Peripheral Blood Mononuclear Cells |
|
|
| Completed | N/A | 45 | NA | Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa | Inflammatory Bowel Disease | 12/17 | 05/18 | | |
ProAct, NCT01078558: A Belgian Registry of HUMIRA® (Adalimumab) in Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis ( ) |
|
|
| Completed | N/A | 5940 | NA | | AbbVie (prior sponsor, Abbott), Veeda Clinical Research | Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis | 01/18 | 01/18 | | |
NCT02413047: Evaluate if Response to Infliximab or Adalimumab May be Regained With an Immunomodulator |
|
|
| Terminated | N/A | 3 | US | Azathioprine, Imuran, 6 mercaptopurine, Methotrexate | Indiana University | Inflammatory Bowel Disease, Ulcerative Colitis, Crohn's Disease | 02/18 | 02/18 | | |
NCT01947816: Special Investigation in Patients With Ulcerative Colitis |
|
|
| Completed | N/A | 1621 | NA | | AbbVie | Ulcerative Colitis | 02/18 | 02/18 | | |
HOPE, NCT02739828: Post Marketing Observational Study (PMOS) to Assess Quality of Life in Swedish Hidradenitis Suppurativa (HS) Patients |
|
|
| Completed | N/A | 24 | Europe | Adalimumab, Humira | AbbVie | Hidradenitis Suppurativa | 03/18 | 03/18 | | |
NCT01464333: Special Investigation (Long-term Investigation) in Patients With Crohn's Disease |
|
|
| Completed | N/A | 511 | NA | | AbbVie (prior sponsor, Abbott) | Crohn's Disease | 03/18 | 03/18 | | |
VALUE, NCT02750800: Post-marketing Observational Study to Evaluate the Incremental Impact of AbbVie's Patient Support Program on Patient Reported Outcomes and Health Resource Utilization in Inflammatory Arthritis, Psoriasis and Inflammatory Bowel Diseases in Hungary |
|
|
| Completed | N/A | 427 | NA | Adalimumab, Humira, ABT-D2E7, AbbVie Care 2.0 | AbbVie | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis, Crohn's Disease, Ulcerative Colitis | 04/18 | 04/18 | | |
NCT01736189: Assessment of Clinical Effectiveness and Safety of Adalimumab and High Dose Methotrexate in Routine Clinical Practice |
|
|
| Completed | N/A | 346 | NA | Adalimumab, Humira, ABT-D2E7 | AbbVie (prior sponsor, Abbott) | Rheumatoid Arthritis | 04/18 | 04/18 | | |
NCT02619552: Impact of Medical Treatment on Sexual Function in Patients With Crohn's Disease |
|
|
| Completed | N/A | 50 | US | Anti-TNF, Remicade, Humira, Cimzia, Steroids, Prednisone, Budesonide | University of Maryland, Baltimore, Vanderbilt University, Milton S. Hershey Medical Center, Mercy Medical Center | Crohn's Disease, IBD | 06/18 | 07/19 | | |
NCT02852850: In Vivo Molecular Imaging Predicts Therapeutic Response in Ulcerative Colitis |
|
|
| Unknown status | N/A | 30 | RoW | | Shandong University | Ulcerative Colitis | 06/18 | | | |
| Completed | N/A | 140 | Europe | Home Based Fecal Calprotectin, IBDoc | Universitaire Ziekenhuizen KU Leuven, Belgian Inflammatory Bowel Disease Research and Development (BIRD) VZW | Crohn Disease, Colitis, Ulcerative | 06/18 | 09/22 | | |
NCT02668640: Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in China |
|
|
| Completed | N/A | 55 | NA | Adalimumab, Humira, ABT-D2E7 | AbbVie | Rheumatoid Arthritis | 06/18 | 08/18 | | |
Complete-PS, NCT01387815: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Psoriasis |
|
|
| Completed | N/A | 662 | Canada | Adalimumab, Humira | AbbVie (prior sponsor, Abbott), Cato Research, JSS Medical Research Inc. | Psoriasis | 06/18 | 06/18 | | |
NCT03258814: A Post-Marketing-Observational Study (PMOS) to Determine the Effectiveness of Combined Adalimumab Treatment and Active Supervised Training in Patients With Axial Spondyloarthritis (axSpA) |
|
|
| Terminated | N/A | 17 | Europe | Active Supervised Training (AST), Standard of Care (SOC) Physiotherapy | AbbVie | Axial Spondyloarthritis | 09/18 | 09/18 | | |
EUREKA, NCT02499263: A Prospective Non-interventional Multicenter Study to Evaluate the Effectiveness of Adalimumab in Korean Patients With Ulcerative Colitis (UC) and Identify Potential Predictors of Clinical Response in Routine Clinical Practice |
|
|
| Completed | N/A | 150 | RoW | | AbbVie | Ulcerative Colitis | 09/18 | 09/18 | | |
NCT02963402: Immunoregulatory Mechanisms of Treg Cells Induced by Tocilizumab |
|
|
| Completed | N/A | 35 | Europe | Tocilizumab, Adalimumab | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Arthritis,Rheumatoid | 10/18 | 10/18 | | |
NCT03352622: Pharmacogenomic in Colombian Patients With Rheumatoid Arthritis |
|
|
| Unknown status | N/A | 372 | RoW | CASES, NO RESPONDERS, CONTROLS, RESPONDERS | Universidad de Antioquia, Hospital Pablo Tobón Uribe | Pharmacological Action | 10/18 | 09/20 | | |
NCT01610947: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity |
|
|
| Completed | N/A | 398 | Europe | Adalimumab, Etanercept, Golimumab or infliximab | University Hospital, Montpellier | Spondyloarthritis | 10/18 | 10/18 | | |
| Completed | N/A | 50 | NA | MTX start, MTX, TNF start, TNF | Region Skane | Rheumatoid Arthritis | 11/18 | 06/19 | | |
NCT02786563: Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate |
|
|
| Withdrawn | N/A | 0 | RoW | | AbbVie | Rheumatoid Arthritis (RA) | 11/18 | 11/18 | | |
HARMONY, NCT02786576: Effectiveness of Adalimumab in Moderate to Severe HidrAdenitis SuppuRativa Patients - a Multi cOuNtry studY in Real Life Setting |
|
|
| Completed | N/A | 236 | Europe, RoW | | AbbVie | Hidradenitis Suppurativa | 01/19 | 01/19 | | |
NCT03056924: Immunogenicity of Influenza, Pneumococcal and Hepatitis B Vaccines in IBD Patients Treated With Vedolizumab |
|
|
| Completed | N/A | 173 | US | Pneumococcal Pneumonia vaccine, PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ), PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA)., Influenza vaccine, Afluria, Fluzone, Hepatitis B vaccine, Energix B | Boston Medical Center | Inflammatory Bowel Diseases | 01/19 | 01/19 | | |
NCT03223012: Impact of AbbVie Care Patient Support Program on Clinical, Health Economic and Patient Reported Outcomes, in Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis, Psoriatic Arthritis, Psoriasis and Axial Spondyloarthritis, in the Portuguese National Health Service |
|
|
| Completed | N/A | 116 | Europe | | AbbVie | Crohn's Disease, Ulcerative Colitis (UC), Rheumatoid Arthritis (RA), Psoriatic Arthritis, Psoriasis, Ankylosing Spondylitis (AS), Non-radiographic Axial Spondyloarthritis | 02/19 | 02/19 | | |
| Completed | N/A | 97 | RoW | | AbbVie | Psoriasis | 04/19 | 04/19 | | |
CONCORDIA, NCT02713295: A Study to Provide Real-world Evidence on the Treatment Goal Achievement Rate, Adherence to and Utilization Patterns of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in Greece |
|
|
| Completed | N/A | 273 | Europe | | AbbVie | Moderate to Severe Plaque Psoriasis | 04/19 | 04/19 | | |
SOLACE , NCT02896920: Canadian Humira Post Marketing Observational Epidemiological Study : Assessing Humira Real-life Effectiveness and Impact on HS Burden of Illness |
|
|
| Completed | N/A | 165 | Canada | | AbbVie | Hidradenitis Suppurativa (HS) | 04/19 | 04/19 | | |
| Completed | N/A | 5442 | Europe | | AbbVie (prior sponsor, Abbott) | Moderate to Severe Plaque Psoriasis | 06/19 | 06/19 | | |
|
|
HS rPMS, NCT03001115: Post-Marketing Surveillance of Adalimumab in Korean Hidradenitis Suppurativa Subjects |
|
|
| Completed | N/A | 17 | RoW | | AbbVie | Hidradenitis Suppurativa (HS) | 07/19 | 07/19 | | |
NCT03925441: Post-Marketing Surveillance Study of Adalimumab in Pediatric Chronic Severe Plaque Psoriasis Patients in Korea |
|
|
| Completed | N/A | 2 | RoW | | AbbVie | Psoriasis | 08/19 | 08/19 | | |
| Terminated | N/A | 68 | Canada | No intervention | The Hospital for Sick Children | Lactation | 09/19 | 09/19 | | |
NCT02087878: A Blood and Tissue Sample Collection Study of Patients Who Have Inflammatory Bowel Disease, Who Have Been Treated With Adalimumab and Who Developed Hepatosplenic T-Cell Lymphoma |
|
|
| Withdrawn | N/A | 0 | Europe | | AbbVie | Crohn's Disease, Ulcerative Colitis (UC), Hepatosplenic T-Cell Lymphoma | 09/19 | 09/19 | | |
NCT03017014: A Study to Assess Safety and Effectiveness of Adalimumab for Treating Children and Adolescents With Crohn's Disease in Real Life Conditions |
|
|
| Terminated | N/A | 62 | Europe | | AbbVie | Crohn's Disease | 10/19 | 10/19 | | |
Adherence, NCT02988674: A Study to Assess Retention Rate, Persistence and in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation |
|
|
| Completed | N/A | 139 | RoW | | AbbVie | Spondylarthritis, Psoriatic Arthritis, Ankylosing Spondylitis (AS) | 10/19 | 10/19 | | |
NCT01559038: Canadian Humira Post Marketing Observational Epidemiological Study Assessing Effectiveness in Psoriatic Arthritis |
|
|
| Completed | N/A | 483 | Canada | | AbbVie (prior sponsor, Abbott), Cato Research, JSS Medical Research Inc. | Psoriatic Arthritis | 11/19 | 11/19 | | |
NCT03389984: Psoriatic Inflammation Markers Predictive of Response to Adalimumab |
|
|
| Completed | N/A | 85 | Europe | cutaneous | Poitiers University Hospital | Psoriasis Vulgaris | 11/19 | 06/20 | | |
PRESHUM, NCT03561649: Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA |
|
|
| Completed | N/A | 50 | Europe | Adalimumab | University Hospital, Grenoble, SINNOVIAL | Spondylitis, Ankylosing | 12/19 | 05/20 | | |
Complete-AS, NCT01387802: Canadian Humira Post Marketing Observational Epidemiological Study: Assessing Effectiveness in Ankylosing Spondylitis |
|
|
| Completed | N/A | 722 | Canada | | AbbVie (prior sponsor, Abbott), JSS Medical Research Inc., Cato Research | Ankylosing Spondylitis | 12/19 | 12/19 | | |
MICA, NCT02856763: Predictive Factors of ANTI-TNF Response in Luminal Crohn's Disease Complicated by Abscess |
|
|
| Completed | N/A | 125 | Europe | | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | CD | 01/20 | 04/20 | | |
NCT02878083: Development of a Biomarker of Efficacy of Vedolizumab (EnTyvio®) in Patients With ulcErative ColiTis (DETECT) |
|
|
| Terminated | N/A | 19 | Europe | VEDOLIZUMAB, entyvio, ADALIMUMAB, HUMIRA | Nantes University Hospital, Takeda, Mauna Kea Technologies, Institut National de la Santé Et de la Recherche Médicale, France | ULCERATIVE COLITIS | 01/20 | 01/21 | | |
PROMETHEE, NCT03110094: Investigation of Immunological and Pharmacological Factors for Response to Adalimumab in Rheumatoid Arthritis |
|
|
| Completed | N/A | 59 | Europe | Adalimumab, Additional Biological Sample, Healthy volunteers, Recovery of blood tubes during a donation | Rennes University Hospital | Rheumatoid Arthritis | 01/20 | 01/20 | | |
ORIENT, NCT02322723: Real Life Evaluation of Rheumatoid Arthritis Patients in Israel Treated With HUMIRA |
|
|
| Withdrawn | N/A | 0 | RoW | | AbbVie | Rheumatoid Arthritis | 02/20 | 02/20 | | |
| Completed | N/A | 100 | Canada | | AbbVie, Cato Research | Ulcerative Colitis | 02/20 | 02/20 | | |
HOPE, NCT03155243: Impact of Humira® Therapy on Ocular Inflammation, Selected Health Care Resource Utilization and Patient Reported Outcomes in Patients With Active Non-infectious Intermediate, Posterior and Panuveitis in Routine Clinical Practice |
|
|
| Completed | N/A | 155 | Europe, RoW | | AbbVie | Uveitis | 02/20 | 02/20 | | |
P @ Work, NCT02362074: Progress at Work - The Impact of Adalimumab on Work Related Productivity in Patients With Rheumatoid Arthritis |
|
|
| Completed | N/A | 401 | Canada | | AbbVie | Rheumatoid Arthritis | 03/20 | 03/20 | | |
NCT02896985: Observational Study Evaluating the Effectiveness of Drug Concentration to Predict the Recapture of Response in Crohn's Disease Patients With Loss of Response ( PRADA ) |
|
|
| Completed | N/A | 98 | Canada | | AbbVie | Crohn's Disease | 03/20 | 03/20 | | |
NCT03703817: Rheumatoid Arthritis Satisfaction Outcome Research |
|
|
| Completed | N/A | 421 | RoW | | Pfizer, Biostatistics, Preventive Medicinte Department, College of Medicine, Yonsei University | Rheumatoid Arthritis | 03/20 | 03/20 | | |
AMORE, NCT02687828: A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients |
|
|
| Completed | N/A | 59 | RoW | | AbbVie | Intestinal Behcet's Disease (BD) | 03/20 | 03/20 | | |
MTX, NCT04196920: Methotrexate-associated Anti-TNF Combination Therapy, the Neglected One ! |
|
|
| Unknown status | N/A | 200 | Europe | | University Hospital, Montpellier, Rennes University Hospital - CHU Pontchaillou | Chronic Inflammatory Bowel Disease | 05/20 | 11/20 | | |
NCT02557295: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With RA |
|
|
| Terminated | N/A | 248 | NA | | Celltrion | Rheumatoid Arthritis | 03/20 | 03/20 | | |
NCT02557308: An Observational Study to Evaluate Safety and Efficacy of Remsima™ in Patients With Ankylosing Spondylitis |
|
|
| Terminated | N/A | 329 | NA | | Celltrion | Ankylosing Spondylitis | 02/21 | 02/21 | | |
NCT01764321: Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors |
|
|
| Completed | N/A | 1723 | Europe | | UCB Pharma SA | Rheumatoid Arthritis | 06/20 | 06/20 | | |
| Unknown status | N/A | 180 | Europe | SinnoTest®, Biotherapy prescription without SinnoTest® software | Hospital San Carlos, Madrid | Arthritis, Rheumatoid | 07/20 | 01/21 | | |
NCT03339102: Post-marketing Surveillance Study of Adalimumab (Humira®) for Non-infectious Intermediate, Posterior, or Panuveitis Patients |
|
|
| Completed | N/A | 158 | RoW | | AbbVie | Non-infectious Intermediate, Posterior and Panuveitis | 07/20 | 07/20 | | |
ADAPT, NCT03236870: A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China |
|
|
| Completed | N/A | 181 | RoW | | AbbVie | Psoriasis | 08/20 | 08/20 | | |
NCT03383263: A Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA®) |
|
|
| Completed | N/A | 70 | RoW | | AbbVie | Polyarticular Juvenile Arthritis | 09/20 | 09/20 | | |
NCT02916017: HUMIRA® Long-term Treatment in Patients With Non-infectious Intermediate-, Posterior-, or Pan-uveitis |
|
|
| Completed | N/A | 259 | Japan | | AbbVie | Uveitis | 10/20 | 10/20 | | |
PEDICAD, NCT03640637: The Role of PET/MRI in the Diagnosis and Treatment of Children and Adolescents With Inflammatory Bowel Diseases |
|
|
| Unknown status | N/A | 75 | Europe | | Odense University Hospital, University of Southern Denmark | Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis | 12/20 | 08/21 | | |
NCT02162472: Videocapillaroscopy Assessment During Systemic Agent Therapy in Psoriasis |
|
|
| Completed | N/A | 19 | US | | Northwestern University, AbbVie | Psoriasis | 12/20 | 12/21 | | |
NCT03886233: Treatment Outcome of Uveitis in Autoimmune Diseases |
|
|
| Unknown status | N/A | 1 | NA | Corticosteroid Series, Immunosuppressive drugs, Biological therapy | Assiut University | Autoimmune Uveitis | 02/21 | 02/21 | | |
NCT05320159: Treatment Effectiveness Among Psoriasis Patients Treated With Cosentyx (Secukinumab) |
|
|
| Completed | N/A | 17743 | US | Secukinumab, Cosentyx | Novartis Pharmaceuticals | Psoriasis | 03/21 | 03/21 | | |
NCT04042792: Characterization of Adalimumab Concentrations in Pediatric Patients With Inflammatory Rheumatic Disease With and Without Methotrexate |
|
|
| Completed | N/A | 28 | Europe | pharmacokinetics (PK) measurement | University Hospital, Basel, Switzerland | Rheumatic Diseases | 06/21 | 06/21 | | |
NCT04200833: Golimumab in Juvenile Idiopathic Arthritis-associated Uveitis Failing Adalimumab |
|
|
| Completed | N/A | 10 | NA | Golimumab | Medical University of Graz | JIA Associated Uveitis | 07/21 | 08/21 | | |
ADMIT, NCT03339089: Real-world Effectiveness of Adalimumab on Health Outcomes in Chinese Patients With Immune-Mediated Inflammatory Diseases |
|
|
| Completed | N/A | 224 | RoW | | AbbVie | Ankylosing Spondylitis (AS), Psoriasis, Rheumatoid Arthritis (RA) | 07/21 | 07/21 | | |
NCT03955861: Ultrasound Enthesitis Response in Psoriatic Arthritis |
|
|
| Completed | N/A | 80 | Europe | adalimumab, Humira, Certolizumab, Cimzia, Etanercept, Enbrel, Golimumab, Simponi, Secukinumab, Cosentyx | Belfast Health and Social Care Trust, British Medical Association, Psoriasis and Psoriatic Arthritis Alliance, Queen's University, Belfast | Psoriatic Arthritis, Psoriasis, Enthesitis | 07/21 | 07/21 | | |
| Completed | N/A | 5302 | Europe, Canada, US, RoW | Vedolizumab, Other Biologic Agents | Takeda | Ulcerative Colitis and Crohn's Disease | 07/21 | 07/21 | | |
EVOLVE-IBERIA, NCT03710486: A Study to Observe Vedolizumab and Anti-tumour Necrosis Factors (Anti-TNFs) Outcomes in Real-world Biologic Ulcerative Colitis (UC) and Crohn's Disease (CD) Participants |
|
|
| Completed | N/A | 409 | Europe | | Takeda | Colitis, Ulcerative, Crohn Disease | 08/21 | 02/22 | | |
NCT04115423: A Retrospective Cohort Study on the Risk of Serious Infections in Rheumatoid Arthritis Patients Receiving Tocilizumab |
|
|
| Unknown status | N/A | 9508 | RoW | Tocilizumab, ACTEMRA, Tumor Necrosis Factor Inhibitor (etanercept, infliximab, adalimumab, and golimumab), ENBREL, REMICADE, HUIMIRA, and SIMPONI | Sungkyunkwan University, Ministry of Food and Drug Safety, Korea | Infection, Rheumatoid Arthritis | 10/21 | 10/21 | | |
NCT03505892: A Study to Investigate the Clinical REsponses in Ankylosing Spondylitis Patients on Adalimumab Therapy in Taiwan (EAST) |
|
|
| Completed | N/A | 28 | RoW | | AbbVie | Ankylosing Spondylitis (AS) | 10/21 | 10/21 | | |
NCT03894956: Observational Study Evaluating Long-Term Safety and Effectiveness of Humira in Patients With Hidradenitis Suppurativa |
|
|
| Completed | N/A | 46 | Japan | | AbbVie | Hidradenitis Suppurativa (HS) | 11/21 | 11/21 | | |
NCT04772248: Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints |
|
|
| Completed | N/A | 105711 | US | Tofacitinib, TNF Inhibitor, infliximab, adalimumab, certolizumab pegol, etanercept, golimumab | Brigham and Women's Hospital | Rheumatoid Arthritis | 12/21 | 12/21 | | |
| Completed | N/A | 105711 | US | Tofacitinib, TNF Inhibitor, infliximab, adalimumab, certolizumab pegol, etanercept, golimumab | Brigham and Women's Hospital | Rheumatoid Arthritis | 12/21 | 05/22 | | |
ChiCTR2100042440: Observation on Qingre Tongluo recipe in the treatment of difficult-to-treat rheumatoid arthritis with heat syndrome and its effect on drug resistance gene |
|
|
| Recruiting | N/A | 75 | | No special treatment ;Do not give any treatment, only before treatment for blood, the group does not consider follow-up treatment, recommended patients to seek medical advice, follow the doctor 's orders ;Continue the original treatment plan ;Methotrexate + folic acid tablets + Adalimumab + Qingre Tongluo Prescription ;Methotrexate + folic acid tablets + adalimumab + simulant | Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine; Yunnan Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of traditional Chinese Medicine, Science and Technology Department of Yunnan Province | difficult-to-treat rheumatoid arthritis | | | | |
NCT03266471: Cytokines and Genes in Therapeutic Response in Crohn's Disease |
|
|
| Completed | N/A | 96 | US | Baseline blood sample, Baseline intestinal biopsies, Crohn's disease activity index (CDAI), Post treatment blood sample, Post treatment intestinal biopsies, Baseline stool sample, Post treatment stool sample | Vanderbilt University Medical Center | Inflammatory Bowel Diseases | 05/22 | 05/22 | | |
NCT04882683: Clinical Study of Cord Blood Mononuclear Cells on Treatment of Hormone-resistant or Hormone-dependent Ulcerative Colitis |
|
|
| Recruiting | N/A | 50 | RoW | Prednisone, Deltacortone, Meticorten, Azathioprine, Imurek, Imurel, Adalimumab, Humira, umbilical cord blood mononuclear cells | Shandong Qilu Stem Cells Engineering Co., Ltd. | Ulcerative Colitis | 06/22 | 12/22 | | |
NCT03808506: Relationship Between Baseline Burden of Disease and TDM in Ulcerative Colitis |
|
|
| Withdrawn | N/A | 29 | Canada | Fecal calprotectin | Lawson Health Research Institute | Ulcerative Colitis | 06/22 | 07/22 | | |
NCT07140666: Analysis of Influence Factors on Osteopenia in Different Treatment of Psoriasis |
|
|
| Completed | N/A | 100 | RoW | | Chongli Yu | Psoriasis | 12/22 | 12/22 | | |
PaS, NCT05957120: Subclinical Impairment of Cardiovascular System in Patients With Psoriasis |
|
|
| Completed | N/A | 100 | Europe | | University Medical Centre Ljubljana | Psoriasis, Inflammation, Endothelial Dysfunction, Metabolic Disturbance, Insulin Resistance, Coagulation Disorder, Thrombocyte Disorders | 09/22 | 11/22 | | |
MESYNAD, NCT04360785: Effect of Two Methotrexate in Sync With the First Adalimumab to Prevent the Immunisation Anti Ada in Spondyloarthritis |
|
|
| Completed | N/A | 124 | Europe | Methotrexate | Assistance Publique - Hôpitaux de Paris | Spondyloarthritis | 09/22 | 02/23 | | |
FLYWAY, NCT06600009: Treatment Persistence of Biologics in Patients with PsA in Japan; Retrospective Cohort Study Using a Claims Database |
|
|
| Completed | N/A | 534 | Japan | Secukinumab, Adalimumab | Novartis | Psoriatic Arthritis | 08/23 | 09/23 | | |
ChiCTR2100046284: Clinical study of cord blood mononuclear cells on treatment of hormone-resistant or hormone-dependent ulcerative colitis |
|
|
| Recruiting | N/A | 50 | | Prednisone+Azathioprine/Adalimumab ;Prednisone+Azathioprine/Adalimumab+umbilical cord blood mononuclear cells | The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine; The Second Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Shandong Provincial Medical Association | ulcerative colitis | | | | |
NCT04875299: Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients |
|
|
| Not yet recruiting | N/A | 480 | RoW | The study is observational | The First Affiliated Hospital of Soochow University, Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Central South University, First Affiliated Hospital of Chongqing Medical University, Tianjin First Central Hospital, Wuxi No. 2 People's Hospital, The First People's Hospital of Changzhou, Affiliated Hospital of Nantong University, Shandong Provincial Hospital, Qingdao Municipal Hospital, Liaocheng People's Hospital, the first affiliated hospital of Liaoning university of traditional Chinese medicine | Ankylosing Spondylitis | 01/23 | 05/23 | | |
NCT05720221: Biologics in Management of Inflammatory Bowel Disease in Egyptian Patients |
|
|
| Completed | N/A | 100 | RoW | | Helwan University | IBD | 01/23 | 01/23 | | |
| Completed | N/A | 174 | Europe | Discontinuation of anti-TNF treatment, Remicade, Remsima, Inflectra, Humira, Simponi, Continuation of anti-TNF treatment | Helse Møre og Romsdal HF, Oslo University Hospital, University of Oslo | Colitis,Ulcerative | 01/25 | 01/25 | | |
| Completed | N/A | 6065 | Europe, Canada, US, RoW | | AbbVie | Chronic Plaque Psoriasis | 02/23 | 02/23 | | |
|
|
|
NCT05291039: Infliximab and Adalimumab in Inflammatory Bowel Disease Patients. |
|
|
| Completed | N/A | 56 | RoW | Infliximab, IFX, Adalimumab, ADA | Rehab Werida | Inflammatory Bowel Diseases | 03/23 | 04/23 | | |
RUN-CD, NCT03108326: Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease |
|
|
| Recruiting | N/A | 900 | Europe | Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra | Ced Service GmbH | Crohn Disease | 03/23 | 03/23 | | |
NCT06563635: Frequency of Tuberculosis in Psoriasis Patients |
|
|
| Completed | N/A | 719 | RoW | | Bezmialem Vakif University | Psoriasis Vulgaris, Tuberculosis | 07/23 | 07/23 | | |
| Not yet recruiting | N/A | 60 | | Adalimumab Solution for Injection | The Eighth Affiliated Hospital Sun Yat-sen University; The Eighth Affiliated Hospital Sun Yat-sen University, The Eighth Affiliated Hospital Sun Yat-sen University | Nail psoriasis | | | | |
NCT04731831: Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response. |
|
|
| Recruiting | N/A | 120 | Europe | | Aalborg University Hospital | Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing | 12/25 | 12/25 | | |
NCT07113834: Characteristics of Ankylosing Spondylitis Associated Uveitis |
|
|
| Completed | N/A | 22 | RoW | Adalimumab, Systemic corticosteroids | Benha University | Uveitis | 09/23 | 08/24 | | |
TIGERS, NCT04261010: TNF and IL23 Blocking Agents Gene Expression Ratios in the Psoriatic Arthritis Synovium_() Study |
|
|
| Completed | N/A | 36 | Europe | Global/single cell gene expression profiles obtained from Synovial biopsies | Cliniques universitaires Saint-Luc- Université Catholique de Louvain, Janssen-Cilag International NV, University Hospital, Ghent | Psoriatic Arthritis | 09/23 | 09/23 | | |
